Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
CNY4.93
+0.12 (+2.49%)
CN SHZ Healthcare Biotechnology
Address
No. 2009, Wangyuan Road 201401
Shanghai, SH, CN
Shanghai, SH, CN
CEO
Jun Xu
Website
raas-corp.com
IPO
2008-06-11
ISIN CNE100000C31
Description
Shanghai RAAS Blood Products Co., Ltd. engages in the research, development, production, and sale of blood products. It provides human albumin, intravenous injection of human immunoglobulin, coagulation factor products, vaccines, diagnostic reagents, and testing services. The company was founded by Kieu Hoang on October 29, 1988 and is headquartered in Shanghai, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY4.93
+0.12 (+2.49%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
40M
Beta
0.31
Float Shares
4.43B
Free Float %
66.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.51% | -0.19% | -4.32% | -15.58% | -19.91% | -16.25% | -22.14% | -22.59% | -30.59% | -74.25% | +182.45% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
4.93
DCF (Unlevered)
8.80
+78.5%
DCF (Levered)
4.98
+1.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.83
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-10.1% Q1'26: -24.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-27.3% Q1'26: -43.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-9.4% Q1'26: +1.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+21.7% ★ Q1'26: +21.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+3.9% ★ Q1'26: +3.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-1.1% ★ Q1'26: -1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.17× Q1'26: 2.59× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.01B
est: 714.00M (+182.0%)
|
2.33B
est: 714.00M (+225.8%)
|
1.93B
est: 2.63B (-26.8%)
|
1.80B
est: 2.49B (-27.6%)
|
2.58B
est: 2.95B (-12.5%)
|
2.76B
est: 2.60B (+6.3%)
|
4.29B
est: 3.60B (+19.2%)
|
6.57B
est: 3.81B (+72.4%)
|
7.96B
est: 7.70B (+3.4%)
|
8.18B
est: 8.73B (-6.4%)
|
7.35B
est: 8.19B (-10.2%)
|
8.74B
8.74B – 8.74B
+6.8% YoY
|
9.33B
9.33B – 9.33B
+6.7% YoY
|
| EBITDA |
944.16M
est: 246.07M (+283.7%)
|
1.21B
est: 246.07M (+393.5%)
|
907.24M
est: 907.41M (0.0%)
|
584.22M
est: 858.48M (-31.9%)
|
1.04B
est: 1.02B (+2.6%)
|
1.17B
est: 895.39M (+30.9%)
|
1.62B
est: 1.24B (+30.4%)
|
2.17B
est: 1.31B (+65.3%)
|
2.48B
est: 2.65B (-6.7%)
|
2.29B
est: 2.70B (-15.1%)
|
1.82B
est: 2.53B (-28.2%)
|
2.70B
2.70B – 2.70B
+6.8% YoY
|
2.88B
2.88B – 2.88B
+6.7% YoY
|
| EBIT |
841.35M
est: 222.75M (+277.7%)
|
1.10B
est: 222.75M (+394.7%)
|
763.98M
est: 821.44M (-7.0%)
|
434.46M
est: 777.14M (-44.1%)
|
896.06M
est: 921.59M (-2.8%)
|
1.02B
est: 810.56M (+25.8%)
|
1.46B
est: 1.12B (+30.3%)
|
1.99B
est: 1.19B (+67.4%)
|
2.32B
est: 2.40B (-3.6%)
|
2.09B
est: 2.46B (-14.9%)
|
1.60B
est: 2.30B (-30.8%)
|
2.46B
2.46B – 2.46B
+6.8% YoY
|
2.63B
2.63B – 2.63B
+6.7% YoY
|
| Net Income |
1.44B
est: 849.27M (+69.8%)
|
1.61B
est: 849.27M (+89.9%)
|
835.83M
est: 1.99B (-58.1%)
|
-1.52B
est: 1.20B (-226.9%)
|
607.89M
est: 1.40B (-56.4%)
|
1.32B
est: 797.56M (+66.0%)
|
1.29B
est: 1.26B (+2.5%)
|
1.88B
est: 2.46B (-23.5%)
|
1.78B
est: 2.26B (-21.3%)
|
2.19B
est: 2.27B (-3.2%)
|
1.58B
est: 2.23B (-29.4%)
|
2.37B
2.37B – 2.37B
+5.9% YoY
|
2.50B
2.50B – 2.50B
+5.6% YoY
|
| SGA |
371.46M
est: 91.19M (+307.4%)
|
352.57M
est: 91.19M (+286.6%)
|
310.86M
est: 336.27M (-7.6%)
|
565.96M
est: 318.13M (+77.9%)
|
632.84M
est: 377.26M (+67.7%)
|
528.98M
est: 331.81M (+59.4%)
|
616.64M
est: 459.23M (+34.3%)
|
706.48M
est: 486.46M (+45.2%)
|
712.75M
est: 983.22M (-27.5%)
|
867.79M
est: 971.78M (-10.7%)
|
803.90M
est: 910.95M (-11.8%)
|
972.56M
972.56M – 972.56M
+6.8% YoY
|
1.04B
1.04B – 1.04B
+6.7% YoY
|
| EPS |
0.29
est: 0.13 (+127.0%)
|
0.33
est: 0.13 (+158.3%)
|
0.17
est: 0.30 (-43.3%)
|
-0.31
est: 0.18 (-272.2%)
|
0.12
est: 0.21 (-42.9%)
|
0.20
est: 0.12 (+66.7%)
|
0.19
est: 0.19 (+0.0%)
|
0.28
est: 0.37 (-24.3%)
|
0.27
est: 0.34 (-20.6%)
|
0.33
est: 0.35 (-4.3%)
|
0.24
est: 0.34 (-29.4%)
|
0.36
0.36 – 0.36
+5.9% YoY
|
0.38
0.38 – 0.38
+5.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-743.12M
OE per share TTM
-0.11
Owner's Yield
-2.12%
Maintenance CapEx ratio
318.88%
Maint CapEx / Avg PPE
27.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 116 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X China Biotech ETF (HKD) 2820.HK | 2.30% | 1.84M | 0.68% |
| 2 | KraneShares MSCI All China Health Care Index ETF KURE | 0.77% | 613.1K | 0.79% |
| 3 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.19% | 71.2K | 0.65% |
| 4 | HSBC MSCI China A UCITS ETF HMCT.L | 0.12% | 159.9K | 0.30% |
| 5 | Samsung KODEX China CSI300 ETF 283580.KS | 0.10% | 206.7K | 0.12% |
| 6 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.07% | 11.8K | 0.65% |
| 7 | Amundi MSCI China A UCITS ETF Acc CNAA.L | 0.07% | 96.2K | 0.35% |
| 8 | iShares MSCI China A ETF CNYA | 0.06% | 145.3K | 0.60% |
| 9 | iShares MSCI China A UCITS ETF CNYA.L | 0.06% | 1.86M | 0.40% |
| 10 | iShares MSCI China A UCITS ETF CNYE.MI | 0.06% | 61.4K | 0.45% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
389.9K
Shares Outstanding
6.64B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hui Lu | Deputy General Manager | — | male |
| Ji Hui Shen | Deputy General Manager | — | male |
| Jun Xu | GM & Vice Chairman | — | male |
| Leqi Chen | Head of Finance | — | male |
| Qin Bing Huang | Deputy General Manager | — | male |
| Xi Zhao | Head of Accounting | — | female |
| Yang Gu | Director of Sales & Marketing | — | male |
| Zheng Liu | Deputy GM & Secretary of Board of Directors | — | male |
| Zhengmin Song | Deputy General Manager | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002252.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
